Risk Factor Control Before Orthopedic Surgery

Overview

This trial is designed to determine the best preoperative management strategy for patients undergoing orthopedic surgery.

Full Title of Study: “Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2, 2018

Detailed Description

OPTIMIZE – OS (Optimization of Pre-surgical Testing with an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events – Orthopedic Surgery) trial is to determine the best management strategy for patients undergoing orthopedic surgery. OPTIMIZE will be a prospective randomized trial that will enroll patients during pre-surgical testing before orthopedic surgery. This trial will investigate different strategies aimed at lowering cardiovascular events following orthopedic surgery. The study will compare an intensive multifactorial intervention comprising behavioral modification and polypharmacologic therapy aimed at several modifiable risk factors versus usual care. The trial hypothesis is that a personalized optimization approach is superior to usual care in reducing a composite of death, myocardial infarction, stroke, transient ischemic attack, myocardial necrosis, venous thromboembolism or thrombosis requiring reoperation at 30-days. Secondary endpoints include length of stay, major bleeding, each individual endpoint from the primary endpoint, and quality of life.

Interventions

  • Drug: Metoprolol
    • 25mg PO BID if the HR is elevated at preadmission testing
  • Drug: Lisinopril
    • 2.5mg PO QD if the HR is elevated at preadmission testing
  • Drug: Atorvastatin
    • 80mg PO QD at preadmission testing
  • Behavioral: Lifestyle counseling
    • Diet, exercise, medication adherance and smoking counseling

Arms, Groups and Cohorts

  • Active Comparator: Treatment
    • Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
  • No Intervention: Control
    • Standard of care

Clinical Trial Outcome Measures

Primary Measures

  • Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism
    • Time Frame: 30 days

Secondary Measures

  • Modified Composite of Cardiovascular Events
    • Time Frame: 30 days
    • the reduction in the composite of death, myocardial infarction, stroke, transient ischemic attack, myocardial necrosis, venous thromboembolism, or reoperation

Participating in This Clinical Trial

Inclusion Criteria

  • • ≥ 21 years of age – Subjects undergoing open orthopedic surgery of the hip, knee or spine – Surgery is scheduled at least 3 days after PAT visit and no more than 14 days. – High risk subject cohort – Coronary artery disease, or – Cerebrovascular disease (prior stroke, TIA or carotid artery disease (>70% stenosis), or – Peripheral artery disease, or – Prior Venous thromboembolism or arterial thromboembolism, or – Age ≥ 60 years and 2 of the following – Renal insufficiency (creatinine clearance < 60ml/min) – Diabetes – COPD – Hypertension – Active smoker or stopped less than 30 days prior to consent – Cancer (excluding BCC) – Heart Failure Exclusion Criteria:

  • • Known intolerance to statins – Subject is already on maximum dose statin (atorvastatin/Lipitor 80mg daily or rosuvastatin/crestor 40mg daily) – Bilateral renal artery stenosis – End stage renal disease (receiving dialysis or CrCl <30ml/min) – Known allergy or intolerance to ACE-inhibitor (other than cough) or Angiotensin receptor blocker (e.g. angioedema, hyperkalemia) – Known allergy or intolerance to beta blockers – Known sick sinus syndrome not treated with permanent pacemaker – Known greater than first degree AV block not treated with a pacemaker – Excessive alcohol intake – Acute Coronary Syndrome requiring hospitalization within 1 month – Stroke within 1 month – Known pregnancy – Severe co-morbid condition with life expectancy < 6 months – Inability to give informed consent or adhere to follow-up as per protocol – Current participation in another investigational drug or device trial

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • NYU Langone Health
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jeffrey Berger, MD, Principal Investigator, NYU School of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.